Fate Therapeutics Stock Buy Hold or Sell Recommendation
| FATE Stock | USD 0.94 0.07 6.93% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Fate Therapeutics is 'Strong Sell'. Macroaxis provides Fate Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding FATE positions.
Check out Fate Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide. Note, we conduct extensive research on individual companies such as Fate and provide practical buy, sell, or hold advice based on investors' constraints. Fate Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Fate |
Execute Fate Therapeutics Buy or Sell Advice
The Fate recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Fate Therapeutics. Macroaxis does not own or have any residual interests in Fate Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Fate Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Fate Therapeutics Trading Alerts and Improvement Suggestions
| Fate Therapeutics generated a negative expected return over the last 90 days | |
| Fate Therapeutics has high historical volatility and very poor performance | |
| Fate Therapeutics has some characteristics of a very speculative penny stock | |
| Fate Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 13.63 M. Net Loss for the year was (186.26 M) with loss before overhead, payroll, taxes, and interest of (104.9 M). | |
| Fate Therapeutics currently holds about 568.85 M in cash with (122.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.86, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Fate Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 90.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Fate Therapeutics, Inc. Receives Average Recommendation of Hold from Analysts - Defense World |
Fate Therapeutics current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Fate analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Fate analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Average Consensus Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Fate Therapeutics Returns Distribution Density
The distribution of Fate Therapeutics' historical returns is an attempt to chart the uncertainty of Fate Therapeutics' future price movements. The chart of the probability distribution of Fate Therapeutics daily returns describes the distribution of returns around its average expected value. We use Fate Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Fate Therapeutics returns is essential to provide solid investment advice for Fate Therapeutics.
| Mean Return | -1.36 | Value At Risk | -11.47 | Potential Upside | 9.29 | Standard Deviation | 6.28 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Fate Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Fate Stock Institutional Investors
| Shares | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 2.8 M | Goldman Sachs Group Inc | 2024-12-31 | 2.5 M | Vestal Point Capital Lp | 2024-12-31 | 2.5 M | State Street Corp | 2024-12-31 | 2.2 M | Geode Capital Management, Llc | 2024-12-31 | 2.2 M | Tang Capital Management Llc | 2024-12-31 | 1.9 M | Orbimed Advisors, Llc | 2024-12-31 | 1.7 M | Jpmorgan Chase & Co | 2024-12-31 | 1.7 M | Jacobs Levy Equity Management, Inc. | 2024-12-31 | 1.6 M | Redmile Group, Llc | 2024-12-31 | 12.9 M | Blackrock Inc | 2024-12-31 | 10.9 M |
Fate Therapeutics Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 82.5M | (33.8M) | (72.3M) | (19.5M) | (10.8M) | (10.2M) | |
| Free Cash Flow | (44.2M) | (213.6M) | (283.8M) | (138.4M) | (123.6M) | (129.8M) | |
| Depreciation | 3.1M | 5.9M | 13.8M | 18.3M | 9.9M | 10.4M | |
| Other Non Cash Items | 111.4M | (18.1M) | (24.3M) | (52.3M) | 12.0M | 12.6M | |
| Capital Expenditures | 4.9M | 50.7M | 35.6M | 6.2M | 730K | 693.5K | |
| Net Income | (173.4M) | (212.2M) | (281.7M) | (160.9M) | (186.3M) | (176.9M) | |
| End Period Cash Flow | 182.6M | 148.8M | 76.6M | 57.0M | 46.3M | 91.4M | |
| Change To Inventory | (4.3M) | (4.3M) | 1.6M | (5.9M) | (5.3M) | (5.1M) | |
| Change To Netincome | 17.4M | 30.8M | 37.3M | 51.8M | 59.6M | 62.5M | |
| Investments | (156.1M) | (273.3M) | 166.8M | 120.4M | 12.2M | 12.8M |
Fate Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Fate Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Fate Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Fate stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -1.15 | |
β | Beta against Dow Jones | 2.04 | |
σ | Overall volatility | 5.90 | |
Ir | Information ratio | -0.2 |
Fate Therapeutics Volatility Alert
Fate Therapeutics is displaying above-average volatility over the selected time horizon. Fate Therapeutics is a potential penny stock. Although Fate Therapeutics may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Fate Therapeutics. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Fate instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Fate Therapeutics Fundamentals Vs Peers
Comparing Fate Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Fate Therapeutics' direct or indirect competition across all of the common fundamentals between Fate Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Fate Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Fate Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Fate Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Fate Therapeutics to competition |
| Fundamentals | Fate Therapeutics | Peer Average |
| Return On Equity | -0.54 | -0.31 |
| Return On Asset | -0.26 | -0.14 |
| Operating Margin | (25.27) % | (5.51) % |
| Current Valuation | (84.53 M) | 16.62 B |
| Shares Outstanding | 114.6 M | 571.82 M |
| Shares Owned By Insiders | 2.26 % | 10.09 % |
| Shares Owned By Institutions | 89.80 % | 39.21 % |
| Number Of Shares Shorted | 13.06 M | 4.71 M |
| Price To Earning | (4.35) X | 28.72 X |
| Price To Book | 0.34 X | 9.51 X |
| Price To Sales | 7.92 X | 11.42 X |
| Revenue | 13.63 M | 9.43 B |
| Gross Profit | (104.9 M) | 27.38 B |
| EBITDA | (176.58 M) | 3.9 B |
| Net Income | (186.26 M) | 570.98 M |
| Cash And Equivalents | 568.85 M | 2.7 B |
| Cash Per Share | 5.86 X | 5.01 X |
| Total Debt | 85.27 M | 5.32 B |
| Debt To Equity | 0.19 % | 48.70 % |
| Current Ratio | 6.55 X | 2.16 X |
| Book Value Per Share | 2.80 X | 1.93 K |
| Cash Flow From Operations | (122.87 M) | 971.22 M |
| Short Ratio | 5.22 X | 4.00 X |
| Earnings Per Share | (1.64) X | 3.12 X |
| Target Price | 5.95 | |
| Number Of Employees | 181 | 18.84 K |
| Beta | 2.26 | -0.15 |
| Market Capitalization | 107.89 M | 19.03 B |
| Total Asset | 440.69 M | 29.47 B |
| Retained Earnings | (1.4 B) | 9.33 B |
| Working Capital | 253.39 M | 1.48 B |
| Current Asset | 47.4 M | 9.34 B |
| Current Liabilities | 14.68 M | 7.9 B |
Note: Acquisition by Dulac Edward J Iii of 425000 shares of Fate Therapeutics at 6.77 subject to Rule 16b-3 [view details]
Fate Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Fate . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Fate Therapeutics Buy or Sell Advice
When is the right time to buy or sell Fate Therapeutics? Buying financial instruments such as Fate Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Fate Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Latest Losers Thematic Idea Now
Latest Losers
Dynamically computed list of top equities currently sorted across major exchanges. The Latest Losers theme has 149 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Latest Losers Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Fate Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fate Therapeutics. If investors know Fate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.64) | Revenue Per Share | Quarterly Revenue Growth 0.11 | Return On Assets | Return On Equity |
The market value of Fate Therapeutics is measured differently than its book value, which is the value of Fate that is recorded on the company's balance sheet. Investors also form their own opinion of Fate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fate Therapeutics' market value can be influenced by many factors that don't directly affect Fate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.